Overview

A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants

Status:
Completed
Trial end date:
2019-07-30
Target enrollment:
0
Participant gender:
All
Summary
The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after administration of a single dose of pirfenidone alone or in combination with BMS-986278
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Pirfenidone
Criteria
Inclusion Criteria:

- Signed Informed Consent.

- Healthy participant, as determined by no clinically significant deviation from normal
in medical history, physical examination, ECGs, and clinical laboratory
determinations.

Exclusion Criteria:

- Women of child bearing potentia (WOCBP), pregnant or breastfeeding.

- History of significant cardiovascular disease.

- Participants who have smoked or used smoking cessation or nicotine containing products
within 3 months of the first dose of study.

Other protocol defined inclusion/exclusion criteria could apply.